CDSCO issues alert as 84 drug batches fail quality tests | Fusion - WeRIndia

Ensuring the safety of medicines is crucial for public health. However, recent quality checks by the Central Drugs Standard Control Organization (CDSCO) have raised serious concerns.

In December 2024, the CDSCO identified 84 batches of medicines that failed to meet quality standards.

These medicines, including those used for treating acidity, diabetes, cholesterol, and bacterial infections, were deemed Not of Standard Quality (NSQ).

This discovery has led to increased scrutiny of pharmaceutical products across India.

The CDSCO’s inspection revealed that these medicines did not comply with the required standards, categorizing them as Not of Standard Quality (NSQ).

However, officials clarified that this failure applies only to the tested batches and not the entire product line.

They emphasized that regular monitoring and coordination with state regulators help identify and remove substandard and counterfeit drugs from the market.

Authorities assured that continuous efforts are in place to detect faulty medicines.

They conduct routine inspections to maintain drug safety and prevent compromised medicines from reaching consumers.

Here are the new guidelines for drug inspections:

To improve quality control, the CDSCO introduced stricter guidelines for drug inspectors. Under the new rule:

• Each inspector must collect at least 10 samples per month (including 9 drug samples and 1 cosmetic or medical device sample).
• The samples must be sent to the laboratory on the same day for testing.
• In remote areas, inspectors can take one additional day to submit samples.

These new measures aim to strengthen drug monitoring and enhance consumer safety.

The failure of medicine batches raises questions about drug safety. Consumers may worry about whether their medications are genuine and effective.

However, authorities are actively addressing these concerns through regular inspections and improved regulatory policies.

With the CDSCO tightening quality control processes, the pharmaceutical industry faces greater accountability.

As regulatory actions intensify, the focus remains on ensuring safe and high-quality medicines for all.

Image from Pxhere (Free for commercial use / CC0 Public Domain)

Image Published on March 04, 2017

Image Reference: https://pxhere.com/en/photo/967274